Evaluation of Bortezomib-Induced Neuropathy Using Total Neuropathy Score (Reduced and Clinical Versions) and NCI CTCAE v4.0 in Newly Diagnosed Patients With Multiple Myeloma Receiving Bortezomib-Based Induction-Reference-Cited by-同舟云学术

Evaluation of Bortezomib-Induced Neuropathy Using Total Neuropathy Score (Reduced and Clinical Versions) and NCI CTCAE v4.0 in Newly Diagnosed Patients With Multiple Myeloma Receiving Bortezomib-Based Induction

Published:2017-08 Issue:8 Volume:17 Page:513-519.e1
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Lakshman Arjun^ORCID,Modi Manish,Prakash Gaurav,Malhotra Pankaj,Khadwal Alka,Jain Sanjay,Kumari Savita,Varma Neelam,Varma Subhash

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference31 articles.

1. Improved survival in multiple myeloma and the impact of novel therapies;Kumar;Blood,2008

2. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients;Kumar;Leukemia,2014

3. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma;Richardson;N Engl J Med,2005

4. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib;Richardson;J Clin Oncol,2006

5. Fresh from the pipeline: bortezomib;Paramore;Nat Rev Drug Discov,2003

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A genetic variant study of bortezomib-induced peripheral neuropathy in Chinese multiple myeloma patients;Oncology Research;2024

2. Mapping chemotherapy-induced peripheral neuropathy phenotype and health-related quality of life in patients with cancer through exploratory analysis of multimodal assessment data;Supportive Care in Cancer;2022-01-21

3. The Potential Role of Proinflammatory Cytokines and Complement Components in the Development of Drug-Induced Neuropathy in Patients with Multiple Myeloma;Journal of Clinical Medicine;2021-10-04

4. Clinical and biochemical markers in CIPN: A reappraisal;Revue Neurologique;2021-10

5. Drug-Induced Peripheral Neuropathy: Diagnosis and Management;Current Cancer Drug Targets;2021-07-20